Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement

Authors: Marcello Lanari, Elisabetta Venturini, Luca Pierantoni, Giacomo Stera, Guido Castelli Gattinara, Susanna Maria Roberta Esposito, Silvia Favilli, Emilio Franzoni, Eleonora Fusco, Paolo Lionetti, Claudio Maffeis, Gianluigi Marseglia, Laura Massella, Fabio Midulla, Alberto Zanobini, Marco Zecca, Alberto Villani, Annamaria Staiano, Luisa Galli, Other Collaborators

Source: Italian Journal of Pediatrics, Vol 48, Iss 1, Pp 1-10 (2022)

Subject Terms: Monoclonal antibody, COVID19, Adolescents, Risk factors, Pediatrics, RJ1-570

File Description: electronic resource

Relation: https://doaj.org/toc/1824-7288

Access URL: https://doaj.org/article/315551fc1cbd4c92a2cda7a6a3e401c0

POS-467 Long-term efficacy and safety of repeated rituximab therapy in children with frequently-relapsing, steroid-dependent nephrotic syndrome: an international multicentre study

Authors: CHAN, E.Y.H., Basu, B., Ghiggeri, G.M., Gillion-Boyer, O., Hogan, J., Ishikura, K., Kamei, K., Hamada, R., Parekh, R., Sinha, R., Vivarelli, M., Xu, H., Yap, H.K., Gipson- M. Kemper & other collaborators, D.S., Tullus, K.

Source: Kidney international reports. 7(S):S208-S208

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCvdc_100155930468.0x000001&indx=1&recIds=ETOCvdc_100155930468.0x000001

The prognostic value of proliferation in lymph-node-negative breast cancer patients is age dependent

Authors: Baak, J. P. A., van Diest, P. J., Voorhorst, F. J., van der Wall, E., Beex, L. V. A. M., Vermorken, J. B., Janssen, E. A. M., Gudlaugsson, E., other collaborators of the Multicenter Morphometric Mammary Carcinoma Pro

Source: EUROPEAN JOURNAL OF CANCER. 43(3):527-535

Availability: http://explore.bl.uk/primo_library/libweb/action/display.do?tabs=detailsTab&gathStatTab=true&ct=display&fn=search&doc=ETOCRN203597380&indx=1&recIds=ETOCRN203597380

Eligibility criteria for pediatric patients who may benefit from anti SARS-CoV-2 monoclonal antibody therapy administration: an Italian inter-society consensus statement.

Authors: Lanari, Marcello, Venturini, Elisabetta, Pierantoni, Luca, Stera, Giacomo, Castelli Gattinara, Guido, Esposito, Susanna Maria Roberta, Favilli, Silvia, Franzoni, Emilio, Fusco, Eleonora, Lionetti, Paolo, Maffeis, Claudio, Marseglia, Gianluigi, Massella, Laura, Midulla, Fabio, Zanobini, Alberto, Zecca, Marco, Villani, Alberto, Staiano, Annamaria, Galli, Luisa, Other Collaborators

Source: Italian Journal of Pediatrics; 1/12/2022, Vol. 48 Issue 1, p1-10, 10p

Subject Terms: DRUG approval, CONSENSUS (Social sciences), COVID-19, COMBINATION drug therapy, MONOCLONAL antibodies, RISK assessment, COMORBIDITY, CHILDREN

Company/Entity: UNITED States. Food & Drug Administration

Proliferation accurately identifies the high-risk patients among small, low-grade, lymph node-negative invasive breast cancers.

Authors: J. P. A. Baak, P. J. van Diest, E. A. M. Janssen, E. Gudlaugsson, F. J. Voorhorst, E. van der Wall, J. B. Vermorken, other collaborators of the Multicenter Morphometric Mammary Carcinoma Project (MMMCP)

Source: Annals of Oncology. Apr2008, Vol. 19 Issue 4, p649-649. 1p.

Subject Terms: *BREAST cancer, *CANCER risk factors, *LYMPH nodes, *CANCER invasiveness, *CANCER cell growth